-
Innovent announces that IBI351 (KRAS G12C inhibitor) Phase I/II clinical study has completed the first patient dosing
Time of Update: 2021-11-05
San Francisco, USA and Suzhou, China September 30, 2021/PRNewswire/ - Cinda Biopharmaceuticals (Hong Kong Stock Exchange stock code: 01801), a company dedicated to R&D, production and sales for the treatment of tumors, metabolic diseases, and its own A biopharmaceutical company that is an innovative drug for major diseases such as immunity, today announced that its KRAS G12C inhibitor IBI351 phase I/II clinical study (ClinicalTrials.
-
Jingfeng Pharmaceutical Subsidiary Received Notification of Approval of Bingzhishangtong Aerosol Drug Supplement Application
Time of Update: 2021-11-05
The main function of the drug is to clear away heat, detoxify and cool blood, promote blood circulation, remove blood stasis and relieve pain .
The benchmark product of Bingzhishangtong aerosol in the current market is Yunnan Baiyao aerosol .
-
Hisun Pharmaceutical's insulin aspart injection was officially approved for the treatment of diabetes
Time of Update: 2021-11-05
Insulin aspart is a fast-acting analogue of human insulin, designed to control hyperglycemia caused by meals in diabetic patients requiring insulin treatment.
Later, it promotes glucose absorption while inhibiting the release of liver glycogen.
Compared with soluble human insulin, the subcutaneous absorption rate is faster .
-
Cefmetazole Sodium for Injection, a wholly-owned subsidiary of Haisco passed the consistency evaluation of generic drugs
Time of Update: 2021-11-05
Haisco was approved for injection of cefmetazole sodium in dosage form, specifications, and indications consistent with the original research, and is currently the second generic drug company to be listed on the market through the consistency evaluation .
-
Qilu meets his rivals!
Time of Update: 2021-11-05
According to data from Meinenet, the sales of terminal esmolol injections in China's public medical institutions will exceed 700 million yuan in 2020, a year-on-year increase of 24.
-
Uncharacteristically!
Time of Update: 2021-11-05
Due to the dismal results of the trial, the FDA believes that the company's gradual cryosurgery treatment does not have enough evidence to support its new drug application .
-
Stabilizing the Boundary of the Fuzzy Volume of the Drug Use Structure——The Deep Meaning of the Volume Purchase of Guangdong Chemical Drugs
Time of Update: 2021-11-05
Following the renewal of contract 45 and 58 Chinese patent medicines, Guangdong’s largest volume of 153 chemical drugs and therapeutic biological products with the same generic name (that is, the same species) with large consumption and high purchase amount, the draft for comments on the procurement plan for the national day Finally surfaced the night before .
-
Secret: 31 drugs or therapies around the world won the Nobel Prize "New Drug Research and Development" What is the next Nobel Prize?
Time of Update: 2021-11-05
For example, the 2019 Nobel Prize in Physiology or Medicine is awarded to scientists who have made important contributions in the field of oxygen sensing pathway research .
-
Zhengda Tianqing broke out!
Time of Update: 2021-11-05
Recently, CP Tianqing Pharmaceutical Group's product line has been frequently updated: colorectal cancer drug trefluridine tepipyrimidine tablets have been approved for marketing, class 1 new drugs TQB2916 and TQB2868 have successively applied for INDs, and 210 million yuan has been introduced to introduce long-acting baiyao.
-
Can the PD-(L)1 double antibody surpass the PD-(L)1 monoclonal antibody?
Time of Update: 2021-11-05
6% better than K drug historical data in the registered phase II clinical treatment of patients with recurrent or metastatic cervical squamous cell carcinoma, and reached 47.
-
A number of Class 1 new drugs were approved for clinical treatment of baldness, atopic dermatitis, etc.
Time of Update: 2021-11-05
They are: Hengrui SHR-1819 injection for the treatment of atopic dermatitis; Luye Pharma’s LPM3770164 sustained-release tablets for use For the treatment of tardive dyskinesia and Huntington's disease; Cody Bio Finasteride spray, topical treatment of mild to moderate male pattern baldness (androgenic alopecia) in 18-41-year-old males, promote hair growth and prevent Hair loss continues; Tianguangshi Bio-recombinant humanized monoclonal antibody MIL62 injection treats systemic myasthenia gravis .
-
Jingding Pharmaceutical strengthens clinical data and digital service capabilities through important appointments
Time of Update: 2021-11-05
Former GSK executive Stephen Pyke will lead the implementation and development of Jingding Pharmaceutical’s clinical data and digital strategy to better utilize data insights to support Jingding Pharmaceutical’s “patient-centric” strategic focusShanghai, October 12, 2021/PRNewswire/ - Parexel, a leading multinational clinical research organization (CRO) dedicated to the development and delivery of innovative therapies to improve human health, recently announced the appointment of Stephen Pyke is the executive vice president of clinical data and digital services .
-
Jinsai Pharmaceutical's recombinant human growth hormone plans to be included in the priority review for children with short stature, etc.
Time of Update: 2021-11-05
According to information on the official website of Jinsai Pharmaceutical, the recombinant human growth hormone injection developed by the company has been approved in China for 8 indications, including growth disorder in girls caused by gonadal hypoplasia (Turner syndrome), which was just approved at the end of September this year.
-
Violation of the 340B drug discount plan!
Time of Update: 2021-11-05
CompilationFan DongdongA few days ago, news showed that many pharmaceutical manufacturers such as Eli Lilly, AstraZeneca, Novartis, Novo Nordisk, Sanofi and United Biotech may face fines for violating the 340B drug discount plan .
-
The first domestic product! Jiangsu pharmaceutical companies attack $2 billion star drug
Time of Update: 2021-11-05
According to data from Meinenet, in 2020, the total sales of dasatinib tablets in Chinese public medical institutions and physical pharmacies in Chinese cities will exceed 500 million yuan, a year-on-year increase of 21% .
-
Bayer assists the Global Self-care Alliance to release the first "Self-care Readiness Index" report
Time of Update: 2021-11-05
Based on the analysis and recommendations of the "Self-care Readiness Index" report, it will give full play to its own advantages and help Promote science-based health projects and innovations that are accessible to the public .
-
STSA-1005 injection, a wholly-owned subsidiary of Shutaishen, obtained clinical trial approval from the U.S. FDA
Time of Update: 2021-11-05
STSA-1005 specifically binds to human GMRα and blocks its interaction with the ligand GM-CSF, thereby negatively regulating the innate immune response .
STSA-1005 injection is independently developed by the company's wholly-owned subsidiary Stadson BioPharma Inc.
-
A number of well-known pharmaceutical companies have been sold to further increase the concentration of the pharmaceutical industry?
Time of Update: 2021-11-05
Kyrgyzstan Pharmaceutical HoldingsKyrgyzstan Pharmaceutical HoldingsOn September 27, Jilin Pharmaceutical Holdings issued a reminder announcement on planning for the sale of major assets and signing the "Share Transfer Framework Agreement", announcing that it would sell 99.
-
BeiGene declares OX40 agonist antibody
Time of Update: 2021-11-05
BGB-A445 mechanism of actionFrom: BeiGene official websiteAccording to the Insight database, BGB-A445 has started phase I clinical trials abroad as early as December 2019, combined with tislelizumab for the treatment of advanced solid tumors .
-
Enhua broke out!
Time of Update: 2021-11-05
Figure 1: New drugs declared by Enhua since 2021Source: CDE official websiteAccording to data from Mi Nei. com, in 2020, in China’s urban public hospitals, county-level public hospitals, urban community centers, and township health centers (referred to as Chinese public medical institutions) terminals, Jiangsu Enhua Pharmaceutical has 7 varieties with sales of over 100 million yuan.
